Wang, MD, of Roswell Park Comprehensive Cancer Center, discussed the evolving role of measurable residual disease (MRD) as ...
In an interview with Targeted Oncology, Eunice S. Wang, MD, of Roswell Park Comprehensive Cancer Center, discussed which ...
Panelists discuss how AML treatment has entered an exciting era of personalized medicine with increasing oral options and targeted therapies, while identifying immunotherapy as a major unmet need and ...
Ziftomenib plus intensive chemotherapy produced high response and MRD negativity rates with manageable safety in newly diagnosed AML. The frontline cohort enrolled 99 patients, including 49 with NPM1 ...
On Tuesday, June 7, Eunice Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, will present the long-term results of a phase 2 clinical trial combining crenolanib, a ...
Please provide your email address to receive an email when new articles are posted on . In this video, Eunice Wang, MD discusses acute myeloid leukemia highlights from the ASH Annual Meeting and ...
Please provide your email address to receive an email when new articles are posted on . In this video, Eunice Wang, MD, discusses the use of venetoclax azacitidine as a standard of care therapy for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results